Skip to main content
Equibles
INDV logo

INDV · Indivior Pharmaceuticals, Inc. · Metrics

Track INDV — free

Use INDV with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research INDV.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$35.38 -0.47 (-1.31%) At close · Oct 1
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$4.23B
Shares
118.01M
Volume · Oct 1 1.88M Avg daily vol (3M) 2.04M

INDV metrics

81 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$35.38
Market cap
$4.23B

Price action

20 metrics
Price change (1W)
-0.2%
Price change (30D)
+3.7%
Price change (3M)
-10.9%
Price change (6M)
+17.0%
Price change (YTD)
-0.1%
Price change (1Y)
+48.7%
Trailing year
Price change (5Y)
+146.4%
52-week high
$41.83
52-week low
$22.73
Change from 52-week high
-14.3%
Change from 52-week low
+57.7%
Annualized volatility
36.9%
Annualized volatility (3M)
29.9%
Beta
0.5
RSI (14D)
49.0
Price vs SMA 50
-3.2%
Price vs SMA 200
+0.3%
Avg volume (3M)
2.03M
Relative volume
0.8
Average dollar volume
$76.25M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
118.01M

Valuation

12 metrics
P / E (TTM)
12.8
Trailing earnings · reciprocal yield 7.8%
PEG ratio
0.0
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
3.2×
reciprocal yield 31.5%
P / book
—
FCF yield
-2.6%
TTM · current market cap
Buyback yield
7.1%
P / FCF
—
P / operating cash flow
—
Earnings yield
8.4%

Historical valuation

8 metrics
P / E historical average (3Y)
20.4×
reciprocal yield 4.9%
P / E historical average (5Y)
20.4×
reciprocal yield 4.9%
EV / revenue historical average (3Y)
2.8×
reciprocal yield 35.5%
EV / revenue historical average (5Y)
2.8×
reciprocal yield 35.5%
EV / EBIT historical average (3Y)
19.4×
reciprocal yield 5.2%
EV / EBIT historical average (5Y)
19.4×
reciprocal yield 5.2%
EV / EBITDA historical average (3Y)
14.5×
reciprocal yield 6.9%
EV / EBITDA historical average (5Y)
14.5×
reciprocal yield 6.9%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
7.1%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-03

Profitability

9 metrics
Gross margin
82.2%
Operating margin
31.6%
Trailing 12 months
Net margin
26.7%
Gross profit (TTM)
$1.09B
Operating profit (TTM)
$421.00M
Net income (TTM)
$356.00M
Trailing 12 months
Diluted EPS (TTM)
$2.79
FCF margin
-8.3%
Effective tax rate
9.7%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-1.35

Growth

11 metrics
Revenue growth YoY
+13.6%
Year over year
Net income growth YoY
+577.8%
Revenue (TTM)
$1.33B
Trailing 12 months
EPS growth YoY
+600.0%
Shares change YoY
-1.6%
Year over year · fewer shares
Revenue CAGR (3Y)
+11.2%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
28.9%
Debt / equity
—
Current ratio
0.8
EBITDA (TTM)
$430.00M
Free cash flow (TTM)
−$111.00M
Quick ratio
0.7
Interest coverage
15.6
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$222.00M
Total assets
$1.23B
Total debt
$487.00M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$40.00M
Capital expenditures (TTM)
$71.00M
R&D (TTM)
$82.00M
SG&A (TTM)
$589.00M
Stock compensation (TTM)
$32.00M
R&D / revenue
6.2%
Stock compensation / revenue
2.4%

Ownership (13F)

3 metrics
13F filers
337
13F filer change QoQ
+46
Institutional ownership
105.7%

Short interest

3 metrics
Short interest
9.5%
Latest settlement · 5.7 days to cover
Days to cover
5.7d
Short-squeeze score
71 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$656,673
Insider-sentiment score
76 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1625297 CUSIP 45579U109 13F (30d) 8 filings 8 filers Visit website Investor relations